Statements Of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities
Net loss	$ (5,887,410)	$ (5,286,720)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	554,361	367,611
Amortization of intangibles	199,321	199,320
Amortization of deferred finance costs	99,998	188,239
Share-based compensation	768,682	1,365,121
Gain on debt extinguishment		(5,632,171)
Noncash interest		485,857
Loss on asset disposal	98,550
Adjustment of warrants	(212,030)	2,009,150
Provisions for obsolete inventory	3,948,726	283,441
Changes in operating assets and liabilities:
Accounts receivable	378,704	1,710,511
Inventories	285,406	(1,136,612)
Prepaid expenses and other current assets	105,215	(187,940)
Other assets	(5,191)	(7,548)
Accounts payable	(968,909)	782,875
Accrued liabilities	(1,295,917)	(1,567,226)
Deferred revenue	(2,959,033)	(181,468)
Other liabilities	214,960	44,806
Net cash used in operating activities	(4,674,567)	(6,562,754)
Cash flows from investing activities
Purchase of fixed assets	(81,577)	(410,184)
Net cash used in investing activities	(81,577)	(410,184)
Cash flows from financing activities
Payments of deferred financing costs	(100,000)	(100,000)
Proceeds from revolving line of credit		7,650,000
Payments of revolving line of credit		(7,650,000)
Payments of Healthcare Royalty Partners debt		(13,020,780)
Proceeds from issuance of stock, net of issuance costs	41,054	23,001,528
Net cash provided by (used in) financing activities	(58,946)	9,880,748
Net increase (decrease) in cash and cash equivalents	(4,815,090)	2,907,810
Cash and cash equivalents at beginning of period	8,501,392	5,593,582
Cash and cash equivalents at end of period	$ 3,686,302	8,501,392
Supplemental disclosures of cash flow information:
Interest paid		$ 2,251,613